Company profile
GeneLink, Inc.
OTC: GNLKQ · Healthcare · Biotechnology
#787 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 45
v0.1 · 5/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ growth stability, market scale
Methodology →Revenue TTM
$1.7M
Rev growth YoY (TTM)
-33.6%
Net income (FY)
-$3.1M
Employees
14
as of 2026-08-29
Market cap
$10.6k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.1M$2.1M2012
Net income-$3.1M-$3.1M2012
Operating income-$3.5M-$3.5M2012
Total assets$1.5M$1.5M2012
Liabilities$4.1M$4.1M2012
Equity-$2.7M-$2.7M2012
Revenue trend
FY2005 – FY2012 · USD
FY05
FY06
FY07
FY08
FY09
FY10
FY11
FY12
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is GeneLink, Inc.’s revenue?
GeneLink, Inc. booked $2.1M in FY2012 revenue, contracting 54% year over year — slower than 83% of Healthcare companies we track, at a -142.9% net margin.
Peers · Healthcare
American Mobile Dental Corp.——Endexx Corporation——BNB Plus Corp.33DAeolus Pharmaceuticals, Inc.——Cyclerion Therapeutics, Inc.40DHealthLynked Corp.34DNeighbors
Orange →Key facts
CEOBernard L. Kasten Jr.
SectorHealthcare
IndustryBiotechnology
HeadquartersOrlando, FL
ExchangeOTC: GNLKQ
Employees14
IPO date1998-11-30
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.